EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are first-line drugs for advanced NSCLC patients with EGFR-activating mutations (Bruckl et al., 2017; Hirsch et al., 2017).